INTERNATIONAL SOCIETY FOR HEART AND LUNG TRANSPLANTATION
(ISHLT) ACADEMY

Core Competency Document (CCD)

Core Competencies in Pediatric and Adult Congenital Heart Disease Ventricular Assist Device Support

(Working Title: Peds MCS CCD)

Supporting Councils: Pediatric Council, Mechanical Circulatory Support and Junior Faculty and Trainee Council

Current Contact:
Angela Lorts, M.D.
Associate Professor Pediatrics
Medical Director, VAD/TAH program
Cincinnati Children's Hospital Medical Center
Cincinnati Ohio 45229
Office: 513 635 4145
Cell: 513 375 8897
Angela. Lorts@cchmc.org

Authors Pediatric MCS Core Competency Document:

Angela Lorts, M.D.
Associate Professor Pediatrics
Director, VAD/TAH program
Cincinnati Children's Hospital
Cincinnati, Ohio, USA
Angela. Lorts@cchmc.org

Chet R Villa, M.D.
Assistant Professor Pediatrics
Staff, VAD/TAH Program
Cincinnati Children's Hospital
Cincinnati, Ohio, USA
Chet.Villa@cchmc.org

Martin Schweiger, M.D., PD, F.E.B.S.
Children`s Hospital Zurich
Department for Cardiovascular Congenital Surgery
Stenwiesstrasse 75
Zurich, Switzerland
Martin.Schweiger@kispi.uzh.ch

Janet Scheel, MD
Professor, Pediatrics
Children's National
Medical Director, Heart Failure and Cardiac Transplant
Washington, DC, USA
Jscheel@childrensnational.org

Jennifer Conway MD, FRCPC
Assistant Professor , Pediatrics
Staff, Heart Transplant and Function
Stollery Children's Hospital
Edmonton, AB, Canada
jennifer.conway2@albertahealthservices.ca

Christina VanderPluym, MD
Assistant Professor, Pediatrics
Director, Ventricular Assist Device Program
Boston Children's Hospital
Boston, MA, USA
Christina.Vanderpluym@cardio.chboston.org

Aamir Jeewa MD
Assistant Professor, Pediatrics
Medical Director, VAD Program
Baylor College of Medicine
Houston, TX, USA
jeewa@bcm.edu

Steven J Kindel, MD
Assistant Professor, Pediatrics
Medical Director, Advanced Heart Failure
Children's Hospital of Wisconsin
Milwaukee, WI, USA
SKindel@chw.org

David LS Morales, MD
Professor, Surgery
Cincinnati Children's Hospital
Medical Center
Cincinnati, OH, USA
David.Morales@cchmc.org

Richard Kirk, MA, FRCP, FRCPCH
Consultant Paediatric Cardiologist
& Transplant Physician
Freeman Hospital
Newcastle Upon Tyne, UK
richardkirk@nhs.net

Charlie Canter, MD
Professor, Pediatrics
Director, Advanced Heart Failure
Washington University
St. Louis, MO, USA
Canter@kids.wustl.edu

Amanda Schubert, RN, BSN
VAD Coordinator
VAD/TAH Program
Cincinnati Children's Hospital
Cincinnati, OH, USA
Amanda.Schubert@cchmc.org

Introduction:

This core competency document provides a practical and concise clinical review for medical professionals to develop understanding and management of ventricular assist devices (VADs) and the Total Artificial Heart (TAH) in children with and without congenital heart disease and adults with congenital heart disease.

The primary objective is to provide a compendium of topics for guided revision for the developing expert in the field. This document is a collaborative effort provided by the ISHLT Pediatric and Mechanical Circulatory Support Councils to use for future learning activity.

The field is experiencing rapid evolution and this manuscript will require further refinement over time. It should not be seen as a comprehensive textbook or substitute thereof. Feedback for the authors is encouraged.

The text is also designed to assist pediatric centers in the development of a comprehensive ventricular assist device support program. It does not replace professional training or credentialing and merely serves to guide professionals in their efforts to study the subspecialty content in their particular clinical setting. It is therefore meant to be a guide for expert development and serves as part of the educational curriculum of the ISHLT. It provides the basis for separate learning activities and self-directed study.

General Learning Objectives:

This document allows learners and participants to develop or improve competence and professional performance in their ability to:

1. Evaluate a patient for VAD implantation including preoperative assessment, planning and optimal timing of implantation
2. Determine the optimal VAD and support strategy for each unique patient.
3. Understand VAD/TAH implantation strategies and intraoperative strategies.
4. Understand, anticipate, recognize, and manage potential adverse events that may occur in pediatric VAD patients.
5. Understand the basic principles of anti-coagulation in this population.
6. Determine the optimal pump settings by using non-invasive monitoring and diagnostic testing, including echocardiography.
7. Evaluate a child for possible discharge on a VAD and prepare for the transition back into the community.
8. Understand the benefits of VAD support while awaiting transplantation in select cases.
9. Recognize the utility of palliative care, preparedness planning and end of life decision making in pediatric VAD patients.

10. Recognize the essential components and long term educational needs of a pediatric VAD program/team.

Table of Contents

Section I: Historical Overview of VAD Use in Pediatrics

Learning Objectives for VADS in pediatrics:

A. Understand the historical perspective and evolving use of VADs in pediatric patients
B. Understand the history of clinical VAD trials in pediatrics
C. Appreciate the impact VAD support has had on heart transplant waitlist morbidity and mortality

1. Historical perspective of pediatric VADs
    a. Early era
        i. Frequency and type of devices employed
            1. Temporary support
            2. Biventricular support
        ii. Patient characteristics and indications
        iii. Clinical outcomes
    b. Recent era
        i. Frequency and type of devices employed
            1. Temporary support
            2. Biventricular support
        ii. Patient characteristics and indications
        iii. Clinical outcomes
2. VAD approvals and clinical trials in pediatrics
    a. DeBakey VAD Child
    b. Berlin EXCOR trial
    c. The Pediatric Circulatory Support Program (PCSP) and PumpKIN trial
    d. Syncardia 50 cc trial
3. Historical perspective on waitlist and transplant outcomes with and without VADs
    a. European Experience
    b. Canadian Experience
    c. US Experience
    d. Asia Experience

Key References:
[1-14]

Section II: Patient Selection for Ventricular Assist Devices

Learning Objectives for selecting the right VAD patient:

A. Understand the indications and optimal timing of device placement, in particular the differences in outcomes between the different INTERMACS classes.
B. Appreciate changes in markers of end-organ function that may drive earlier VAD placement.
C. Define the importance of determining the intent of the device therapy.
D. Understand the high-risk pediatric VAD populations that may be better bridged to transplant with medical management.

1. Appreciate literature regarding optimal timing of implantation
    a. Adult experience: INTERMACS I/II vs III/IV
    b. Pediatric experience from the Berlin trials
2. End-organ function screening
    a. Renal function
        i. Cystatin C
        ii. Nuclear GFR
    b. Hepatic Function
        i. INR
        ii. Fibrosis
        iii. Bilirubin
    c. Respiratory
        i. Positive Pressure Ventilation
    d. Nutrition
        i. Pre-albumin/ albumin
        ii. Frailty – adult experience
    e. Neurologic
3. Decision model for deciding to stabilize first on short term device (center specific)
    a. End-organ recovery with ECMO/Short term device
    b. Family consent and education regarding future options
4. Preoperative Planning: Determine degree of support needed
    a. Left ventricular support
    b. Biventricular
        i. Adequacy of RV function
            1. RV scoring systems in adults
            2. Pediatric BiVAD experience
            3. Berlin heart experience
            4. Era effect
5. Define the indications for therapy
    a. Inotrope dependent
        i. Additional end-organ dysfunction
        ii. Unable to maintain nutrition
    b. Post-cardiotomy failure to wean from CPB
    c. Unable to tolerate oral medications

    d. Uncontrollable Arrhythmias
    e. Tumor
    f. Restrictive cardiomyopathy unresponsive to medical therapy
6. Define the intent for therapy
    a. Bridge to Decision
    b. Bridge to Transplant
    c. Bridge to Recovery
    d. Bridge to a Bridge
    e. Chronic (destination) therapy
7. To discuss the unique populations that may be followed in a pediatric center
    a. ACHD (see also section VII)
        i. Fontan
        ii. Sennings/Mustards
        iii. ccTGA
        iv. Complex with residual lesions
        v. Other
    b. Neonatal/infant single ventricles
        i. Shunted
        ii. Glenn
    c. Muscular dystrophies
        i. The Duchene's muscular dystrophy experience
    d. Chemotherapy-induced cardiomyopathy
    e. Metabolic and genetic syndromes associated to heart failure
8. Ethics of determining which children will be destination vs. bridge to transplant
    a. DMD
    b. Recent chemotherapy
    c. Developmental delay
9. Literature review of complex populations: When may medical management be optimal when compared to VAD implantation as a bridge to transplant?
    a. Single ventricle patients
    b. Neonates
    c. Myocarditis
    d. Patients with contraindication to anti-coagulation
    e. Difficult social situations/non-adherence

Key References:

[4, 15-24]

Section III: Ventricular Assist Device Selection: Short-Term Devices

Learning objectives for Short-Term Devices:

A. Understand the indications and contraindications for the use of short-term mechanical circulatory support in pediatric patients.
B. Understand the short-term MCS devices and their associated outcomes in pediatric patients.
C. Understand the role of rapid resuscitation ECMO or "eCPR" after cardiopulmonary arrest and the clinical outcomes associated.
D. Understand basic patient management for children supported on ECMO or short-term continuous flow mechanical circulatory support.
E. Understand the process of weaning a patient from either ECMO or short-term continuous flow mechanical circulatory support.
F. Understand the process of converting a patient from short-term MCS to more long-term VAD support.

1. Indications for short-term support
    a. Reversible etiology for cardiac dysfunction
        i. Myocarditis
        ii. Acute Heart Transplant Rejection
        iii. Other
    b. Inadequate RV function
    c. Pulmonary disease and ECMO
    d. Septic shock and ECMO
    e. Intractable, malignant arrhythmias
    f. Post-cardiotomy failure
    g. Unknown candidacy for long term support
2. Contraindications for short term MCS support
    a. Multi-organ failure
    b. Refractory infections or severely immunosuppressed states
    c. Untreatable conditions (e.g end-stage metastatic cancer or severe CNS injury)
    d. Inability to obtain vascular access
    e. Unable to accept blood products or tolerate anticoagulation
    f. Progressive or severe neurological injury
3. ECMO outcomes
    a. Congenital heart disease
    b. Myocarditis
    c. Cardiomyopathy
    d. Post-cardiotomy failure
4. Current devices used for short term support
    a. ECMO
        i. Components
            1. Pump
            2. Heater
            3. Oxygenator
        ii. Highlighting the differences in veno-venous (VV) ECMO versus veno-arterial (VA) ECMO
    b. Pedimag/Centrimag centrifugal ventricular support
    c. Rotaflow centrifugal ventricular support

    d. Impella
        i. 2.5
        ii. 5.0
        iii. RP
    e. Tandem Heart
    f. Intra-aortic balloon pump
    g. Other
5. Patient management
    a. Device selection
        i. Emergent
            1. eCPR
        ii. Acute
            1. ECMO: Peripheral cannulation vs central cannulation
                a. Strategies for peripheral cannulation
            2. Short term VAD
    b. Managing inotropic support on short term support
        i. Vasodilator therapy to optimize flow
        ii. Inotropic support as appropriate for right ventricular support
    c. Ventilator management
        i. Lung preserving settings
        ii. Preparing for support wean/decannulation
    d. Left atrial decompression (with ECMO)
        i. Diagnosing left atrial hypertension
            1. Echo
            2. Chest x-ray
        ii. Therapy
            1. Atrial septostomy
            2. Left atrial or ventricular vent (surgical)
            3. Left ventricular support
                a. Percutaneous short term support
            4. Surgical placement of VAD
    e. Anticoagulation (see also anticoagulation section)
        i. Heparin infusion
            1. Monitoring parameters
                a. ACT
                b. PTT
                c. Anti-Xa levels
                d. Thromboelastography
            2. Optimization
                a. Monitoring AT3 levels
                b. AT3 replacement
            3. Heparin induced thrombocytopenia
        ii. Balancing bleeding and clotting
            1. Starting heparin
            2. Risk of events and time since support initiation
        iii. Inflammation/Infection and anticoagulation
        iv. Monitoring the circuit for fibrin/thrombus
    f. Assessment myocardial function on support
        i. Invasive and non-invasive assessment of recovery
            1. Hemodynamic assessment

2. Echocardiography

ii. Staged wean of circuit flows

1. ECMO
2. LVAD

Key References:

[1, 7, 8, 25-39]

Section IV: Ventricular Assist Device Selection – Long-Term Devices

Learning objectives for Long-term Devices:

A. Understand various device selection algorithm for children of all sizes and ages (country and center-specific).
B. Know the relative indications and contraindications for the use of long-term support in pediatrics.
C. Understand the differences in the flow dynamics of currently available devices.
D. Recognize the long-term VAD support strategies and understand the various bridge therapies.
E. For US clinicians, Identify the FDA approved indications for all the commonly used devices.
F. Describe the pediatric experience of long-term continuous flow devices.
G. Recognize the various VADs available for children and adult patients with end stage congenital heart diseases (ACHD)
H. Recognize limitations and advantages of different VAD types (extra-corporeal vs. intra-corporeal)

1. Characteristics of currently available durable continuous flow devices
    a. Ages of children that can be implanted with currently available devices
    b. Industry recommends for size, in patients >1.5 m^2
    c. Devices approved for destination
    d. Common Devices
        i. HeartMate II (Thoratec)
            1. Axial flow
            2. Requires pump pocket
            3. Larger device, unlikely to fit in most children
            4. Pocket controller has back up battery, benefit to adolescents
        ii. HVAD (HeartWare)
            1. Centrifugal flow
            2. Pericardial device
            3. Smaller device, used in children as small as 0.7m^2
        iii. Jarvik 2000
2. Characteristics of currently available durable pulsatile devices *
    a. Devices
        i. Berlin Heart EXCOR
            1. Only FDA approved device for children (US)
            2. Pneumatic
            3. Can be used as Bivad
            4. All sizes

5. Unable to discharge (US)

ii. TAH-t (Syncardia)

1. Two sizes (50cc and 70 cc)
2. FDA approved for adults (70 cc)
3. Trial underway for children
4. Must have BSA>1.7m^2 (70 cc)

iii. Other

1. P-VAD
2. Toyobo
3. Berlin InCOR
4. Reliant

4. Initiatives for miniaturizing of pumps
    a. Decreasing shear stress
    b. Need for minimal anti-coagulation
5. VADS that are soon to be available in Europe and North America to follow
    a. Syncardia 50 cc TAH
    b. Circulite (HeartWare)
    c. MVAD (HeartWare)
    d. HeartMate III (Thoratec)
    e. HeartMate X (Thoratec)
    f. Jarvik 2000 (PumpKIN trial)
    g. Other

Key References:

[40-49]

Section V: Surgical Implantation

Learning objectives for surgical implantation:

A. **Understand VAD-type selection algorithm based on patients weight, anatomy, illness, bridge strategy (bridge to transplant, recovery, decision, long-term support) in the various countries.**
B. **Learn relevant surgical techniques including children with congenital heart diseases (CHD) and grown-up/adults after palliation of CHD.**
C. **Recognize new peri-operative diagnostic tools for VAD placement in children.**
D. **Understand the pitfalls and perils of VAD implantation in the pediatric and ACHD population including pre-existing valve pathology.**
E. **Appreciate improvements in device design, technology, peri-operative management and implantation technique.**

1. Surgical implantation (unique considerations in children)
    a. LVAD placement and cannulation techniques
    b. Continuous flow VAD in small patients
    c. Implantation in patients with failing surgically palliated CHD
    d. Management/placement of drivelines
2. Surgical cannulation techniques for RVAD
3. Special considerations in the uni-ventricular heart (see also below)
4. Concomitant Cardiac Surgery
    a. Aortic valve insufficiency
    b. Atrio-ventricular valve regurgitation
    c. Intracardiac and extracardiac shunts
    d. Artificial valves
5. Novel Diagnostic Procedures to Determine Device "fit"
    a. CT reconstrucution
    b. Virtual implantation
    c. Three dimensional models
6. Weaning form Cardiopulmonary Bypass
    a. Inotrope management
    b. De-airing
    c. Protecting the right ventricle
    d. Bleeding
    e. Chest Closure

Key References:
17, 50-58

Section VI: Support Strategies for the Single Ventricle Patient

Learning Objectives for Support strategies for the single ventricle:

A. Review the different cardiac malformations leading to palliative single ventricle repair
B. Recognize the consequences of palliative single ventricle repair and critical time points of possible failure.
C. Understand anatomical and surgical challenges in patients after palliative single ventricle repair.
D. Learn different MCS and cannulation strategies at different time points for the staged palliative single ventricle repair.
E. Review new diagnostic tools including especially imaging methods for patients how underwent palliative sing ventricle repair.
F. Understand how to diagnose a `failing fontan`.
G. Recognize treatment options in patients suffering from end-stage heart failure with Fontan circulation.

1. Anatomical variations and etiology of failure
    a. Cardiac malformations leading to palliative single ventricle repair
    b. Staged single-ventricle repair
        i. Norwood Stage I
        ii. Glenn
        iii. Fontan
    c. Physiology of a Fontan Circulation
    d. Issues in the growing child with the Fontan Circulation
2. Support and cannulation strategies for all stages
    a. Single-ventricle patients with circulatory failure following Norwood I procedure
    b. Single-ventricle patients with circulatory failure following superior cavopulmonary anastomosis (Glenn)
    c. Single-ventricle patients with circulatory failure following total cavo- pulmonary connection (Fontan)
    d. Recognizing the need for multicenter collaboration to assess MCS in single ventricle patients
3. Evaluation of the Failing Fontan patient
    a. Clinical and laboratory examination
    b. Echocardiographic Evaluation of palliated single-ventricle patients
    c. CT and MRI imaging in ACHD and Fontan Circulation
    d. Invasive measurements (including cardiac catheterization and invasive hemodynamic monitoring)
    e. Stages of the failing Fontan circulation
4. Treatment options for the Failing Fontan
    a. Medical optimization
    b. Surgical options (Including Fontan conversion, transplantation, TAH, Take-down, Fenestration, MCS)
    c. Palliative Care

Key References:
59-66

Section VII: Support Strategies for Adult Congenital Heart Disease Patients

Learning Objectives for adult congenital heart disease support:

A. **Understand the dramatic differences between the VAD implantation rates of adults with CHD vs non-CHD adults waiting for transplant and how this effects their waitlist time and mortality.**
B. **Understand VAD options at various centers for complex CHD including when a TAH may be the best option.**
C. **Better appreciate the high rates of sensitization and end-organ dysfunction in this patient population and how this may effect support decision making.**
D. **Understand the needs and differences in device selection between typical adult heart failure patients and children/adults with congenital heart disease.**

1. Increasing prevalence of adult congenital heart disease
2. Heart failure prevalence and outcomes in ACHD: defining areas of need for MCS
    a. Evaluating heart failure symptoms in ACHD
    b. Medical therapies
    c. Electrophysiology and heart failure
        i. Sinus node dysfunction
        ii. Atrial dysrhythmias
        iii. AV node dysfunction
        iv. Dysynchrony/Resynchronization
    d. Arrhythmias and sudden death
        i. Atrial
        ii. Ventricular
3. Causes of heart failure and MCS outcomes (if available) in specific lesions
    a. Ventricular interaction
        i. Tetralogy of Fallot
        ii. Ebsteins
    b. Transposition
        i. Atrial switch patients
        ii. cc-TGA patients with systemic ventricular failure
    c. Single ventricle physiology
4. Sensitization with long term VAD support
    a. Waitlist outcomes and sensitization
    b. Post-transplant outcomes and the sensitized patient
    c. Sensitization risk in congenital patients independent of VAD support
        i. Understanding cytotoxic versus non-cytotoxic Sensitization
    d. Available desensitization therapies

Key References:
[50, 67-102]

Section VIII: Post-operative ICU Care of the Ventricular Assist Device Patient

Learning Objectives for Routine Post-Operative Care of the VAD Patient:

A. Discuss the routine post-operative care for patients supported on continuous flow devices to prevent adverse events.
B. Discuss routine post-operative care for Berlin Heart patients to prevent adverse events.
C. Discuss the routine post-operative care for TAH patients to prevent adverse events.
D. Appreciate the importance of establishing hemostasis in the early post-operative period.

1. Device specific hemodynamic goals
    a. Continuous flow device hemodynamic goals
        i. Cardiac index goals
            1. Non-invasive indices adequate
            2. RPM and Watts within goal
        ii. Adequate blood pressure control to optimize flow
        iii. Careful fluid management
    b. Berlin Heart EXCOR hemodynamic goals
        i. Calculated CI by pump size and rate
            1.Non-invasive indices adequate
        ii. Blood pressure control not as essential
        iii. Full fill and full eject by visualization
    c. Total artificial heart
        i. Cardiac index adequate; as calculated by fill and rate
        ii. Adequate after-load control
        iii. Partial fill, full eject
2. Right heart support for LVAD
    a. Decrease PVR
        i. Obtain FRC with optimal ventilator settings
        ii. Consider iNO or PGE
        iii. Avoid acidosis
    b. Inotropes
    c. Slow gentle diuresis
    d. Careful management of heart rate
    e. Adjust LVAD settings to optimize RV
3. Antibiotics
    a. Prophylaxis approaches
        i. Drug resistant organisms
        ii. +/- anti-fungal prophylaxis
4. Hemostasis
    a. Avoidance of quick reversal of anti-coagulation
    b. Blood product use and potential avoidance
    c. Pump parameters consistent with tamponade
5. Physiology that may complicate post-operative care
    a. Intracardiac shunts
    b. Collaterals
    c. AV valve regurgitation

d. Contraction around inflow cannula

Section IX: Review of Post-Operative Adverse Events

Learning Objectives for Routine Post-Operative Care of the VAD Patient:

A. Identify common adverse events encountered in pediatric patients on a VAD.
B. Identify treatment options for post-operative right heart failure.
C. To discuss the literature pertaining to device infections and ways to prevent them.
D. Appreciate the signs of pump thrombosis and the different treatment options for various devices.
E. Understand indications for pump exchange in the setting of thrombosis for both continuous flow and pulsatile VADs.
F. Assessment and management of hemorrhagic or thrombotic stroke in patients on MCS
G. Recognize interventions to improve long term neurological recovery.

1. Right Heart Failure
    a. Current definitions for right heart failure
    b. Frequency of occurrence
    c. Assessment of right ventricular failure
        i. Clinical parameters
            1. CVP
            2. Edema
            3. Hepatomegaly
            4. Renal dysfunction
            5. Changes in flow and fill
        ii. Hemodynamics
        iii. Parameters from the LVAD
        iv. Imaging modalities: echocardiogram
            1. Septal shift
            2. Tricuspid regurgitation
    d. Incidence of right ventricular failure following left ventricular assist device (LVAD) insertion
        i. Adult data
        ii. Pediatric Data
    e. Risk factors for development of right ventricular failure post-LVAD implantation
        i. Etiology of heart disease more likely to present with biventricular failure
        ii. Markers pre-operatively that can predict failure, including adult scoring systems
        iii. Role of pre-operative pulmonary hypertension
    f. Outcomes of right ventricular failure following LVAD insertion
        i. Impact on mortality
        ii. Impact on end-organ function
        iii. Impact on LVAD functioning
    g. Intraoperative strategies for prevention of right ventricular failure
        i. Techniques for coming off bypass
        ii. Use of inhaled nitric oxide

iii. Importance of minimization of bleeding
iv. Use of continuous ultra filtration
v. Role of inotropes and vasodilators
vi. Role of LVAD

h. Management of RV failure in the post-operative period including both medical and device strategies
i. Medical strategies: nitric oxide, pulmonary vasodilators, inotropes
ii. Mechanical ventilations strategies
iii. Right ventricular assist devices (temporary)

2. Bleeding and Tamponade
a. The definition of major bleeding
i. Review InterMACs and PediMACS definitions
ii. Frequency of occurrence
b. The scope of the problem
i. Berlin Heart EXCOR data
ii. Adult continuous flow pump data
iii. Early vs. Late bleeding
c. Risk factors for post operative bleeding
i. ECMO
ii. Previous surgeries
iii. Pre-op anticoagulation
d. Clinical presentation of tamponade in a VAD patients (LVAD or BIVAD)
e. Management strategies for major bleeding
i. Alteration of anticoagulation (reversal or lowering)
ii. Surgical interventions

3. Post-Operative Stroke
a. Definition of device related stroke
b. Frequency of this adverse event
c. Management algorithm for cerebrovascular events
i. Neurology service
ii. Neuroimaging
iii. Baseline assessment of hemostasis (anticoagulation and antiplatelet testing, TEG)
iv. Available protocols for alterations in anticoagulation and antiplatelet therapies in response to hemorrhagic or ischemic events
d. Identifying and quantifying neurological injury
i. Role of physical examination
ii. Role of imaging
1. Importance of pre-operative imaging
iii. Defining deficit through imaging and prognosticating deficit through physical examination
e. Risk stratifying patients based on
i. Size and location of deficit
ii. Hemorrhagic vs ischemic- does it matter?
iii. Degree of physical impairment
f. Restarting unfractionated heparin: when, and how much
g. Monitoring neurological function
i. Surveillance imaging
ii. Role of physical examination
iii. Role of PT and OT

iv. Promoting neurological recovery

4. Driveline infections
    a. Definitions of driveline infections
        i. ISHLT definitions
    b. Frequency of driveline infections in children on VADS
    c. Risk factors for developing a driveline infection
    d. Diagnosis and evaluation of driveline infections
        i. Role of swabs and blood cultures
        ii. Role of imaging studies (ultrasound, CT and echocardiogram)
    e. Medical and surgical management strategies for driveline infections
        i. Medical:
            1. Antibiotic therapy (IV vs. po)
            2. Suppressive therapy
            3. Dressing changes
        ii. Surgical:
            1. Debridement
            2. Pump exchange or removal
            3. Transplant
    f. To describe potential mechanisms for prevention of driveline infections
        i. Suppressive therapy
        ii. Identifying lifestyle issues
5. Pump Thrombosis
    a. Diagnosis
        i. Signs of Hemolysis
            1. Rising LDH and plasma free HGB
            2. Dark urine
            3. Changes in VAD parameters
                a. Continuous flow VADS
                    i. Change in Watts and calculated flow
                    ii. Change in PI or pulsatility index
                    iii. Ramp study
                b. Berlin Heart EXCOR
                    i. Visual thrombus vs fibrin
                    ii. Change in CO
    b. Treatment
        i. Heparin treatment and observation
        ii. Pump change out (especially in the Berlin patients)
        iii. Catheter directed TPA
        iv. Use of alternative anticoagulation strategies for recurrent pump thrombosis
        v. Surgical removal of thrombosed pump

<u>Key References:</u>

20, 103-127

Section X: Anticoagulation Management

Learning Objectives for anticoagulants and their use:

A. Describe the normal coagulation pathway and how the mechanisms of the commonly used anti-coagulation medications.
B. Understand the indications for anticoagulation medications in the pediatric population and currently available anti-coagulation medications.
C. Explain challenges and benefits of anticoagulation management for mechanical circulatory support (dosing, dose titration, and monitoring)
D. Understand center variations in anti-thrombotic practices worldwide as it pertains to pediatric ventricular device support.
E. Understand different tests for measuring anticoagulation and antiplatelet effect.
F. Appreciate and understand the variability, precision, and reliability of current testing for anticoagulation and antiplatelet effect.
G. Describe current anti-thrombosis protocols as they pertain to anti-thrombosis monitoring and testing.
H. Understand the impact of inflammation on hemostasis.
I. Understand the role of steroids for decreasing inflammation- When? Why? How much? And for how long?
J. Describe the spectrum of complications that may arise secondary to anti-thrombotic therapies as they pertain to sub- or supra-therapeutic anticoagulation and antiplatelet medications.
K. Appreciate the complexity of restarting anticoagulation post hemorrhagic and ischemic cerebrovascular events.

1. The coagulation pathway
    a. Intrinsic pathway
    b. Extrinsic pathway
2. Mechanisms of action of the commonly used anti-coagulation/anti-platelet medications
    a. Heparin
    b. Low molecular weight heparin
    c. Argatroban
    d. Biliverdin
    e. Warfarin
    f. Aspirin
    g. Dipyridamole
    h. Role of sildenafil, milrinone and inhaled nitric oxide
3. Current anti-thrombosis practices in early post-operative period (<7 days)
    a. Berlin devices
        i. Anticoagulation therapy
        ii. Antiplatelet therapy
        iii. Optimal device parameters to prevent thrombosis
    b. Continuous flow devices

        i. Anticoagulation therapy
        ii. Antiplatelet therapy
    c. TAH
        i. Anticoagulation therapy
        ii. Antiplatelet therapy
4. Current anti-thrombosis practices in late post-operative period (>7 days)
5. Alternative anticoagulation options
    a. Indications for alternative/novel anticoagulation
        i. Treatment failure with standard anticoagulation (pump thrombosis or TE events)
        ii. Heparin Induced Thrombocytopenia (HIT)
    b. Types of alternative/novel anticoagulation medications
        i. Oral medications
        ii. Intravenous medications
        iii. Subcutaneous medications
    c. Dosing and monitoring of alternative anticoagulation medications
        i. Oral medications
        ii. Intravenous medications
        iii. Subcutaneous medications
    d. Challenges of alternative anticoagulation strategies
        i. Monitoring
        ii. Reversibility
        iii. Pharmacokinetics and pharmacodynamics in pediatrics
    e. Benefits of alternative anticoagulation strategies
        i. Monitoring
        ii. Adverse event profile
        iii. Non responders to traditional anticoagulation strategies
6. Examples of difficult clinical cases
    a. Anti-thrombosis management with acute hemorrhagic cerebrovascular event
    b. Recurrent pump thrombosis despite optimal anticoagulation and antiplatelet therapy
    c. Recurrent bleeding events with standard anticoagulation therapy
    d. Management of anti-coagulation during interventional or operative procedures including ICD placement
7. Current available testing for anticoagulation and antiplatelet
    a. PTT, PT, anti-Xa level assays, thrombin time
    b. INR
    c. Thromboelastogram (TEG) with platelet mapping
    d. ROTEM
    e. VerifyNow point of care
    f. Urine thromboaxane
8. Correlation between testing
    a. PTT and anti-Xa levels
    b. PTT and anti-Xa assay variability and the role of thrombin
    c. INR laboratory and point of care correlation (when to trust and when not to trust)
9. Intrinsic pro-coagulant and anti-coagulants
    a. Developmental hemostasis
    b. Inflammation and infection
    c. Other medication effect (Milrinone, nitric oxide, nutritional supplements)

    d. Impact on anticoagulation and antiplatelet testing
10. Pro and anti-coagulant effect of inflammation
    a. Key Inflammatory markers
        i. CRP
        ii. ESR
        iii. Metalloproteinases
        iv. WBC
        v. Novel inflammatory markers
        vi. PET imaging
11. Monitoring inflammation
    a. Markers
    b. Timing of testing
12. Steroids and inflammation
    a. Criteria for initiation
    b. Dosing
    c. Monitoring effect
    d. Adverse effects: immunosuppression, risk of infection, wound healing
13. When to increase or decrease anticoagulation with inflammation
    a. Risk stratifying patients through comprehensive coagulation testing (role of TEG, ROTEM, platelet mapping in addition to standard assessment of coagulation)

Key References:
115, 116, 128-145

Section XI: Optimization of Ventricular Assist Device Settings

Learning Objectives for Optimization of Ventricular Assist Device Settings:

1. **Identify methods to monitor for adequate cardiac output while on support.**
2. **Identify echocardiographic findings that may alter device management.**
3. **Discuss settings and parameters on the different VADS that may give the care providers insight to device issues.**
4. **Discuss monitoring for myocardial recovery on a VAD.**

1. Invasive and Non-invasive monitoring of CO
    a. Early post-operative monitoring
        i. NIRS, mixed Venous Sat
        ii. CVP, RAP, LAP
        iii. End organ indices
        iv. Urine output monitoring
        v. LFTs, renal function, other biomarkers
    b. Late post-operative monitoring
        i. Mean arterial pressure & clinical exam
        ii. Device specific monitoring
    c. Echocardiographic parameters
        i. Septal position
        ii. Aortic valve opening and aortic insufficiency
        iii. Assessment of right heart function
            a. RV Dimensions, Tricuspid regurgitation
2. Device Specific Monitoring
    a. Recognize the inaccuracies associated with the device flow estimates
        i. Berlin Heart – Visual Inspection: full eject & full fill
        ii. HVAD- Speed, power, waveforms
        iii. HeartMate II- Speed, power, pulsatility index
        iv. Jarvik 2000
        v. Total artificial heart- CO, fills, waveforms, partial fill & full eject
3. Exercise testing
    a. 6 minute walk
    b. VO2 by treadmill, bike etc
4. End-organ recovery
    a. Renal function
    b. Pulmonary compliance
    c. Hepatic function
    d. Muscle strength, nutrition
5. Echocardiographic
    a. Pre-operative Evaluation
        i. Chamber size evaluation
        ii. Evaluation for thrombus
        iii. Atrial septal inspection for PFO/ASD
        iv. Aortic valve assessment – monitoring for AI
        v. Pulmonary valve – PI or significant PS/dysplasia

vi. Mitral valve – inflow velocity, chordal obstruction
vii. Tricuspid valve: TR velocity and severity, TS

b. Post-operative implantation
    i. LV size
    ii. Inflow cannula placement
    iii. Septal position (goal of neutral)
        a. Over-emptying: R->L bowing; diminutive LV
        b. Under-emptying: large LV, poor inflow Doppler
    iv. LA volume
    v. Inflow cannula position
        a. Position by 2D or 3D
    vi. RV size and function
    vii. Mitral valve insufficiency
    viii. Monitor outflow graft
    ix. Pericardium for effusion

c. Monitoring for pump malfunction
    i. Multi-modality including clinical, biomarkers, pump settings, CT, US
        a. Inflow malfunction
            i. Inflow cannula obstruction, malposition, hyperdynamic LV apical function
            ii. Cannula thrombosis
                A. Other intracardiac thrombosis
        b. Chamber obliteration/underfilling
            i. LVAD induced ectopy
        c. Outflow malfunction
            i. Kinking or thrombus
        d. Significant AI due to cannula misplacement

d. Monitoring for recovery
    i. Repeat echocardiogram at lower support
    ii. Continuous flow VAD
        a. Ramp study
        b. RPM reduction for 2-4 weeks
            i. Repeat echo imaging and clinical testing
            ii. Review of data and protocols
    iii. Pump stop with Berlin Heart
        a. With or without Dobutamine stress
        b. Review of data and protocols

6. Running your VADs at lower RPMs than recommended: What are the risks. What do we know?
    a. London/U of L experience with recovery protocol in adults
        i. Intensive medication approach
        ii. Weaning of RPM and follow up
    b. Parameters to consider before weaning
        i. EF, LVED, and pump goals
        ii. RV function
        iii. Patient goals
    c. Thrombosis risk
        i. Is a change in anti-thrombotics warranted
7. Chronic use and myocardial recovery
    a. Optimal settings for recovery

b. Medications used for remodeling
c. Monitoring for recovery with decreasing settings/Echo parameters and exercise testing
d. Anti-coagulation management during wean or trial off
e. Explant in the patient that has recovered

Key References:
146-152

Section XII: Discharging a Pediatric Patient Back into the Community

Learning Objectives for Discharging a Pediatric Patient Back into the Community:

A. Understand education and training of parents, school personnel and paramedics for home discharge.
B. Recognize the importance of school integration for children.
C. Understand important medical and social obstacles impacting success at home on VAD support.
D. Learn the needs of pediatric patients discharged on VAD support.
E. Learn outpatient management (ex: timing, echocardiographic follow-up, adjusting pump speed to the needs of children at home).
F. Recognize reasons for readmissions and complications for outpatient management.
G. Learn psychosocial considerations of children discharged home on LVAD and safety of typical childhood activities on VAD support.

1. Discharge Planning and Teaching
    a. Essential issues to consider before discharge
    b. Patient criteria for discharge
    c. Draft of a discharge protocol
2. Education and Training
    a. Emergency Algorithm for EMS/Paramedics/Primary Care Physicians
    b. Family Centered Simulations
    c. Practical Workshop
    d. Essential principles for Preparation for school integration
3. Equipment for Home
    a. Practical hands-on training
4. Practical VAD Simulation Workshop
5. Outpatient Care and Anti-Coagulation Team
    a. Trouble-shooting for outpatients
    b. Anticoagulation and activities
    c. Reasons for re-admission: what we can and can't learn from the adults

Key References:
40, 153-156

Section XIII: Preparing for Cardiac Transplant

Learning Objectives for preparing for cardiac transplant:

A. Recognize the increased rate of sensitization associated with VAD therapy.
B. Understand the importance of optimizing nutrition and providing a cardiac rehabilitation program while patients await cardiac transplant.
C. Understand the data regarding transplant outcomes in patients supported with a VAD while waiting.

1. Sensitization while on a VAD
    a. Adult experience (see also section VII)
    b. Pediatric experience

2. VAD/TAH explantation for transplantation
    a. Management of anti-coagulation during time from organ acceptance to OR
    b. Technical aspects and going on cardiopulmonary bypass
3. Rehabilitation
    a. Transitioning to floor
    b. Cardiac rehabilitation programs
    c. Differences in goals between various centers to achieve prior to transplant activation
4. Optimizing nutrition to improve post-transplant outcomes
5. Transplant outcomes post pediatric VAD support

Key References:
91-102, 157-163

Section XIV: Pediatric VAD Program Development for Children and Adults Congenital Heart Disease

Learning objectives for Pediatric VAD Program Development:

A. Understand the structure required to start a program, including identifying core team, education plans and determining what devices that your institution will purchase.
B. Define the role of improvement science in VAD programs including how to determine quality metrics and initiatives to improve outcomes.

1. Essential members of the team
    a. Champion

    b. Surgeon
    c. Perfusion
    d. VAD Coordinator
    e. Hematology
    f. Laboratory partners
    g. Physical/occupational therapy
    h. Social work
    i. Consultants
        i. Neurology
        ii. Infectious Disease
2. Define the equipment components of a pediatric VAD program by support duration and determine feasibility for your program
    a. Short-term support
        i. ECMO
        ii. Temporary continuous flow devices
            1. Rotaflow (Maquet)
            2. CentriMag/PediMag (Thoratec)
            3. Other
        iii. Percutaneous
            1. Tandem Heart
            2. Impella
            3. Aortic Balloon Pump
            4. Other
    b. Long-term support strategies
        i. Berlin
        ii. HeartMate II (Thoratec)
        iii. HVAD (HeartWare)
        iv. TAH (Syncardia)
        v. Jarvik 2000
        vi. Other
3. Define the types of devices needed in a pediatric VAD program by patient size
    a. Neonates
        i. Pedimag
        ii. Berlin
    b. School Aged
        i. Centrimag or Rotaflow
        ii. Berlin
        iii. HeartWare
    c. Adolescents
        i. Centrimag or Rotaflow
        ii. HeartWare
        iii. Heart Mate II
4. Define a biventricular support strategy for your institution
    a. Syncardia
    b. Bi-Ventricular HVAD
    c. Bi-Ventricular Berlin
    d. Short-term RV support with durable left side device
5. The compliance and regulatory issues required to use off label devices
    a. Approved ages
    b. Industry size recommendations

6. Various educational models that could be effective
    a. For parents/families/patients
    b. Human factors testing
        i. Adult devices being used off label
    c. For nurses/ancillary staff
        i. End users
        ii. Code team
    d. For core team
        i. Industry trained core
    e. Community health care providers
        i. EMS
        ii. School
7. Process to define quality metrics and improvement initiatives
    a. Various centers experience
    b. Importance of working with other centers
8. Registries
    a. PediMACS
    b. INTERMACS

Section XV: Simulation And Education of the Team

Learning objectives for Simulation and Education of the Team:

A. Understand the importance of all 3 aspects of education: simulation training, hands on experience, and didactics.
B. Define common scenarios that are well received with simulation training.

1. How to establish a VAD education program
    a. Adequate personnel required to train the team
    b. Didactics
    c. Hands on
        i. Set up
        ii. Alarm troubleshooting
    d. Simulation training
        i. Learning from ECMO
        ii. Learning from surgical simulation
    e. Maintaining proficiency
        i. Initial and annual competency
        ii. Just-in-time training
        iii. Daily bedside device rounds
        iv. Knowledge assessment

2. Hands on Simulations for pediatric VAD programs
    f. Personnel that is needed for a simulation
        i. Bedside nurse
        ii. VAD coordinator
        iii. Medical Provider
        iv. Family members
    g. Goals
        i. System check
        ii. Latent safety threats
        iii. Team dynamics
    h. Location: in-situ or in simulation center
    i. Examples of simulation experiences:
        i. Right heart failure
        ii. Dehydration of an Outpatient
        iii. HTN Crisis
        iv. Device failure

Key References:

164-168

Section XVI: Specialized VAD Core Team Education

Learning objectives for Specialized VAD Core Team Education:

A. Understand the importance of having identified VAD core team members who have received specialized training to troubleshoot devices.
B. Recognize the importance of a training curriculum that aims at educating providers on pediatric and ACHD VAD specific issues.

1. Recognize the Need for Pediatric VAD training and Core Competencies
    a. Complexity of Diseases and Diagnostic Evaluation
    b. Risks of wrong device selection
    c. Importance of continuity
    d. Ownership of anti-coagulation
2. Multidisciplinary Team of:
    a. VAD Coordinator
    b. Surgery
    c. Perfusion
    d. Nursing
    e. Providers
3. Roles and Responsibilities of Team
    a. Initial evaluation
    b. Daily follow up
    c. Dressing changes
    d. Patient and family education
    e. Develop care guidelines
    f. Monitor and support medical team
    g. 24/7 on call coverage

Section XVII: Difficult Decisions: End-Of Life Care of the Pediatric Heart Failure Patient

Learning Objectives for Palliative Care in Pediatric MCS patients:

A. **Understand the tools available to assess quality of life in pediatric and adult congenital heart disease VAD patients.**
B. **Understand the importance of advanced medical directives in the pediatric VAD supported patient.**
C. **Understand the impact of chronic (destination) therapy or discontinuation of care on families.**
D. **Understand the need for multi-institutional pediatric palliative care research and quality improvement initiatives.**

1. Review of current QoL available and current best practices for assessing adequate pain control
    a. PedsQL 4.0
    b. Seattle Heart Failure Score
2. Advanced directives role in MCS care:
    a. Review current legal requirements in many States for patients with poor prognosis.
    b. Involve patient in decision-making process if possible
    c. Ensure that parents and healthcare providers have shared mental model
3. Review of common psychiatric difficulties in MCS patients
    a. Depression
    b. Anxiety
    c. Post-traumatic Distress
    d. Insomnia
4. There is a major impact of the families of pediatric patients with MCS:
    a. Review coping strategies: religion, life philosophy, etc.
    b. Impact of bereavement on family especially siblings (survivor guilt, parental overprotection, etc)
5. Destination or chronic therapy in pediatrics:
    a. Destination device therapy in the pediatric population
    b. Financial burden of destination therapy
    c. Ethics of discontinuing mechanical support
    d. Expected symptoms /course with discontinuation
    e. Role of palliative care
    f. Establishment of DNR/DNI and decisions regarding when to return to hospital
6. Review obstacles to effective pediatric palliative care research:
    g. Inadequate funding
    h. Inadequate researcher workforce
    i. Public and professional misunderstanding of palliative and discomfort with end of life.
    j. Differences between adult and pediatric palliative care

References

1. Fiser WP, Yetman AT, Gunselman RJ, Fasules JW, Baker LL, Chipman CW, Morrow WR, Frazier EA and Drummond-Webb JJ. Pediatric arteriovenous extracorporeal membrane oxygenation (ECMO) as a bridge to cardiac transplantation. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2003;22:770-7.
2. Reinhartz O, Keith FM, El-Banayosy A, McBride LR, Robbins RC, Copeland JG and Farrar DJ. Multicenter experience with the thoratec ventricular assist device in children and adolescents. *J Heart Lung Transplant*. 2001;20:439-48.
3. Stiller B, Hetzer R, Weng Y, Hummel M, Hennig E, Nagdyman N, Ewert P, Lehmkuhl H and Lange PE. Heart transplantation in children after mechanical circulatory support with pulsatile pneumatic assist device. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2003;22:1201-8.
4. Hetzer R, Potapov EV, Stiller B, Weng Y, Hübler M, Lemmer J, Alexi-Meskishvili V, Redlin M, Merkle F and Kaufmann F. Improvement in survival after mechanical circulatory support with pneumatic pulsatile ventricular assist devices in pediatric patients. *The Annals of thoracic surgery*. 2006;82:917-925.
5. Blume ED, Naftel DC, Bastardi HJ, Duncan BW, Kirklin JK and Webber Sa. Outcomes of children bridged to heart transplantation with ventricular assist devices: A multi-institutional study. *Circulation*. 2006;113:2313-2319.
6. Arabia FA, Tsau PH, Smith RG, Nolan PE, Paramesh V, Bose RK, Woolley DS, Sethi GK, Rhenman BE and Copeland JG. Pediatric bridge to heart transplantation: application of the Berlin Heart, Medos and Thoratec ventricular assist devices. *J Heart Lung Transplant*. 2006;25:16-21.
7. Almond CS, Singh TP, Gauvreau K, Piercey GE, Fynn-Thompson F, Rycus PT, Bartlett RH and Thiagarajan RR. Extracorporeal Membrane Oxygenation for Bridge to Heart Transplantation Among Children in the United States Analysis of Data From the Organ Procurement and Transplant Network and Extracorporeal Life Support Organization Registry. *Circulation*. 2011;123:2975-2984.
8. Fraser CD, Jaquiss RDB, Rosenthal DN, Humpl T, Canter CE, Blackstone EH, Naftel DC, Ichord RN, Bomgaars L, Tweddell JS, Massicotte MP, Turrentine MW, Cohen Ga, Devaney EJ, Pearce FB, Carberry KE, Kroslowitz R and Almond CS. Prospective Trial of a Pediatric Ventricular Assist Device. *New England Journal of Medicine*. 2012;367:532-541.
9. Slaughter MS, Rogers JG, Milano CA, Russell SD, Conte JV, Feldman D, Sun B, Tatooles AJ, Delgado III RM and Long JW. Advanced heart failure treated with continuous-flow left ventricular assist device. *New England Journal of Medicine*. 2009;361:2241-2251.
10. Aaronson KD, Slaughter MS, Miller LW, McGee EC, Cotts WG, Acker MA, Jessup ML, Gregoric ID, Loyalka P, Frazier OH, Jeevanandam V, Anderson AS, Kormos RL, Teuteberg JJ, Levy WC, Naftel DC, Bittman RM, Pagani FD, Hathaway DR and Boyce SW. Use of an intrapericardial, continuous-flow, centrifugal pump in patients awaiting heart transplantation. *Circulation*. 2012;125:3191-200.
11. Baldwin JT, Borovetz HS, Duncan BW, Gartner MJ, Jarvik RK and Weiss WJ. The national heart, lung, and blood institute pediatric circulatory support program: a summary of the 5-year experience. *Circulation*. 2011;123:1233-40.
12. Cabrera AG, Sundareswaran KS, Samayoa AX, Jeewa A, Dean McKenzie E, Rossano JW, Farrar DJ, Howard Frazier O and Morales DL. Outcomes of pediatric patients supported by the HeartMate II left ventricular assist device in the United States. *The Journal of Heart and Lung Transplantation*. 2013;32:1107-1113.
13. Cassidy J, Dominguez T, Haynes S, Burch M, Kirk R, Hoskote A, Smith J, Fenton M, Griselli M, Hsia TY, Ferguson L, Van Doorn C, Hasan A and Karimova A. A longer waiting

game: bridging children to heart transplant with the Berlin Heart EXCOR device--the United Kingdom experience. *J Heart Lung Transplant*. 2013;32:1101-6.
14. Adachi I, Khan MS, Guzmán-Pruneda FA, Fraser CD, Mery CM, Denfield SW, Dreyer WJ, Morales DLS, McKenzie ED and Heinle JS. Evolution and impact of ventricular assist device program on children awaiting heart transplantation. *The Annals of thoracic surgery*. 2015;99:635-40.
15. Almond CS, Morales DL, Blackstone EH, Turrentine MW, Imamura M, Massicotte MP, Jordan LC, Devaney EJ, Ravishankar C, Kanter KR, Holman W, Kroslowitz R, Tjossem C, Thuita L, Cohen Ga, Buchholz H, St. Louis JD, Nguyen K, Niebler Ra, Walters HL, Reemtsen B, Wearden PD, Reinhartz O, Guleserian KJ, Mitchell MB, Bleiweis MS, Canter CE and Humpl T. Berlin heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. *Circulation*. 2013;127:1702-1711.
16. Lietz K, Long JW, Kfoury AG, Slaughter MS, Silver MA, Milano CA, Rogers JG, Naka Y, Mancini D and Miller LW. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era implications for patient selection. *Circulation*. 2007;116:497-505.
17. Takayama H, Soni L, Kalesan B, Truby LK, Ota T, Cedola S, Khalpey Z, Uriel N, Colombo P, Mancini DM, Jorde UP and Naka Y. Bridge-to-decision therapy with a continuous-flow external ventricular assist device in refractory cardiogenic shock of various causes. *Circulation Heart failure*. 2014;7:799-806.
18. Matthews JC, Koelling TM, Pagani FD and Aaronson KD. The right ventricular failure risk scorea pre-operative tool for assessing the risk of right ventricular failure in left ventricular assist device candidates. *Journal of the American College of Cardiology*. 2008;51:2163-2172.
19. Fitzpatrick III JR, Frederick JR, Hsu VM, Kozin ED, O'Hara ML, Howell E, Dougherty D, McCormick RC, Laporte CA and Cohen JE. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical circulatory support. *The Journal of Heart and Lung Transplantation*. 2008;27:1286-1292.
20. Zafar F, Jefferies JL, Tjossem CJ, Bryant R, Jaquiss RDB, Wearden PD, Rosenthal DN, Cabrera AG, Rossano JW, Humpl T and Morales DLS. Biventricular Berlin Heart EXCOR Pediatric Use Across the United States. *The Annals of thoracic surgery*. 2015.
21. Weinstein S, Bello R, Pizarro C, Fynn-Thompson F, Kirklin J, Guleserian K, Woods R, Tjossem C, Kroslowitz R and Friedmann P. The use of the Berlin Heart EXCOR in patients with functional single ventricle. *The Journal of thoracic and cardiovascular surgery*. 2014;147:697-705.
22. Ryan TD, Jefferies JL, Sawnani H, Wong BL, Gardner A, Del Corral M, Lorts A and Morales DL. Implantation of the HeartMate II and HeartWare left ventricular assist devices in patients with duchenne muscular dystrophy: lessons learned from the first applications. *ASAIO J*. 2014;60:246-8.
23. Oliveira GH, Dupont M, Naftel D, Myers SL, Yuan Y, Tang WH, Gonzalez-Stawinski G, Young JB, Taylor DO and Starling RC. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol*. 2014;63:240-8.
24. Hoganson DM, Boston US, Gazit AZ, Canter CE and Eghtesady P. Successful bridge through transplantation with berlin heart ventricular assist device in a child with failing fontan. *Ann Thorac Surg*. 2015;99:707-9.
25. Hopper AO, Pageau J, Job L, Heart J, Deming DD and Peverini RL. Extracorporeal membrane oxygenation for perioperative support in neonatal and pediatric cardiac transplantation. *Artif Organs*. 1999;23:1006-9.

26. Morales DLS, Zafar F, Rossano JW, Salazar JD, Jefferies JL, Graves DE, Heinle JS and Fraser CD. Use of ventricular assist devices in children across the United States: Analysis of 7.5 million pediatric hospitalizations. *Annals of Thoracic Surgery*. 2010;90:1313-1318.
27. Morales DL, Almond CS, Jaquiss RD, Rosenthal DN, Naftel DC, Massicotte MP, Humpl T, Turrentine MW, Tweddell JS, Cohen GA, Kroslowitz R, Devaney EJ, Canter CE, Fynn-Thompson F, Reinhartz O, Imamura M, Ghanayem NS, Buchholz H, Furness S, Mazor R, Gandhi SK and Fraser CD, Jr. Bridging children of all sizes to cardiac transplantation: the initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device. *J Heart Lung Transplant*. 2011;30:1-8.
28. Fan Y, Weng Y-G, Huebler M, Cowger J, Morales D, Franz N, Xiao Y-B, Potapov E and Hetzer R. Predictors of in-hospital mortality in children after long-term ventricular assist device insertion. *Journal of the American College of Cardiology*. 2011;58:1183-90.
29. Hetzer R, Loebe M, Potapov EV, Weng Y, Stiller B, Hennig E, Alexi-Meskishvili V and Lange PE. Circulatory support with pneumatic paracorporeal ventricular assist device in infants and children. *Ann Thorac Surg*. 1998;66:1498-506.
30. del Nido PJ, Dalton HJ, Thompson AE and Siewers RD. Extracorporeal membrane oxygenator rescue in children during cardiac arrest after cardiac surgery. *Circulation*. 1992;86:II300-4.
31. Kane DA, Thiagarajan RR, Wypij D, Scheurer MA, Fynn-Thompson F, Emani S, del Nido PJ, Betit P and Laussen PC. Rapid-response extracorporeal membrane oxygenation to support cardiopulmonary resuscitation in children with cardiac disease. *Circulation*. 2010;122:S241-8.
32. Thiagarajan RR, Laussen PC, Rycus PT, Bartlett RH and Bratton SL. Extracorporeal membrane oxygenation to aid cardiopulmonary resuscitation in infants and children. *Circulation*. 2007;116:1693-700.
33. Jeewa A, Manlhiot C, McCrindle BW, Van Arsdell G, Humpl T and Dipchand AI. Outcomes With Ventricular Assist Device Versus Extracorporeal Membrane Oxygenation as a Bridge to Pediatric Heart Transplantation. *Artificial Organs*. 2010;34:1087-1091.
34. Kotani Y, Chetan D, Rodrigues W, Sivarajan VB, Gruenwald C, Guerguerian AM, Van Arsdell GS and Honjo O. Left atrial decompression during venoarterial extracorporeal membrane oxygenation for left ventricular failure in children: current strategy and clinical outcomes. *Artif Organs*. 2013;37:29-36.
35. Hanna BD. Left atrial decompression: Is there a standard during extracorporeal support of the failing heart? *Crit Care Med*. 2006;34:2688-9.
36. Jacobs JP, Ojito JW, McConaghey TW, Boden BD, Chang AC, Aldousany A, Zahn EM and Burke RP. Rapid cardiopulmonary support for children with complex congenital heart disease. *Ann Thorac Surg*. 2000;70:742-9; discussion 749-50.
37. Naidu SS. Novel percutaneous cardiac assist devices: the science of and indications for hemodynamic support. *Circulation*. 2011;123:533-43.
38. Koeckert MS, Jorde UP, Naka Y, Moses JW and Takayama H. Impella LP 2.5 for left ventricular unloading during venoarterial extracorporeal membrane oxygenation support. *J Card Surg*. 2011;26:666-8.
39. Andrade JG, Al-Saloos H, Jeewa A, Sandor GG and Cheung A. Facilitated cardiac recovery in fulminant myocarditis: pediatric use of the Impella LP 5.0 pump. *J Heart Lung Transplant*. 2010;29:96-7.
40. Schweiger M, Vanderpluym C, Jeewa A, Canter CE, Jansz P, Parrino PE, Miera O, Schmitto J, Mehegan M, Adachi I, Hübler M and Zimpfer D. Outpatient management of intracorporeal left ventricular assist device system in children: a multi-center experience. *American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons*. 2015;15:453-60.

41. Schweiger M, Schrempf J, Sereinigg M, Prenner G, Tscheliessnigg KH, Wasler A, Krumnikel J, Gamillschegg A and Knez I. Complication profile of the berlin heart excor biventricular support in children. *Artificial organs*. 2013;37:730-735.
42. Miller JR, Boston US, Epstein DJ, Henn MC, Lawrance CP, Kallenbach J, Simpson KE, Canter CE and Eghtesady P. Pediatric Quality of Life while Supported with a Ventricular Assist Device. *Congenit Heart Dis*. 2015;10:E189-96.
43. Lowry AW, Adachi I, Gregoric ID, Jeewa A and Morales DL. The potential to avoid heart transplantation in children: outpatient bridge to recovery with an intracorporeal continuous-flow left ventricular assist device in a 14-year-old. *Congenit Heart Dis*. 2012;7:E91-6.
44. Geidl L, Deckert Z, Zrunek P, Gottardi R, Sterz F, Wieselthaler G and Schima H. Intuitive use and usability of ventricular assist device peripheral components in simulated emergency conditions. *Artif Organs*. 2011;35:773-80.
45. Schima H, Schloglhofer T, Hartner Z, Horvat J and Zimpfer D. Importance of linguistic details in alarm messages of ventricular assist devices. *Int J Artif Organs*. 2013;36:406-9.
46. Adachi I and Fraser CD, Jr. Mechanical circulatory support for infants and small children. *Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu*. 2011;14:38-44.
47. Biefer HR, Sundermann SH, Emmert MY, Hasenclever P, Lachat ML, Falk V and Wilhelm MJ. Experience with a "hotline" service for outpatients on a ventricular assist device. *Thorac Cardiovasc Surg*. 2014;62:409-13.
48. MacIver J, Ross HJ, Delgado DH, Cusimano RJ, Yau TM, Rodger M, Harwood S and Rao V. Community support of patients with a left ventricular assist device: The Toronto General Hospital experience. *Can J Cardiol*. 2009;25:e377-81.
49. Schweiger M, Vierecke J, Stiegler P, Prenner G, Tscheliessnigg KH and Wasler A. Prehospital care of left ventricular assist device patients by emergency medical services. *Prehosp Emerg Care*. 2012;16:560-3.
50. Shah NR, Lam WW, Rodriguez FH, Ermis PR, Simpson L, Frazier OH, Franklin WJ and Parekh DR. Clinical outcomes after ventricular assist device implantation in adults with complex congenital heart disease. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2013;32:1-6.
51. Peng E, O'Sullivan JJ, Griselli M, Roysam C, Crossland D, Chaudhari M, Wrightson N, Butt T, Parry G, MacGowan GA, Schueler S and Hasan A. Durable ventricular assist device support for failing systemic morphologic right ventricle: early results. *Ann Thorac Surg*. 2014;98:2122-9.
52. Miller JR, Lancaster TS and Eghtesady P. Current approaches to device implantation in pediatric and congenital heart disease patients. *Expert Rev Cardiovasc Ther*. 2015;13:417-27.
53. John R, Naka Y, Park SJ, Sai-Sudhakar C, Salerno C, Sundareswaran KS, Farrar DJ and Milano CA. Impact of concurrent surgical valve procedures in patients receiving continuous-flow devices. *The Journal of thoracic and cardiovascular surgery*. 2014;147:581-9; discussion 589.
54. Robertson JO, Naftel DC, Myers SL, Prasad S, Mertz GD, Itoh A, Pagani FD, Kirklin JK and Silvestry SC. Concomitant aortic valve procedures in patients undergoing implantation of continuous-flow left ventricular assist devices: An INTERMACS database analysis. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2014.
55. Milano C, Pagani FD, Slaughter MS, Pham DT, Hathaway DR, Jacoski MV, Najarian KB and Aaronson KD. Clinical outcomes after implantation of a centrifugal flow left ventricular assist device and concurrent cardiac valve procedures. *Circulation*. 2014;130:S3-11.

56. Moore RA, Madueme PC, Lorts A, Morales DL and Taylor MD. Virtual implantation evaluation of the total artificial heart and compatibility: Beyond standard fit criteria. *The Journal of Heart and Lung Transplantation*. 2014;33:1180-1183.
57. Sodian R, Weber S, Markert M, Loeff M, Lueth T, Weis FC, Daebritz S, Malec E, Schmitz C and Reichart B. Pediatric cardiac transplantation: Three-dimensional printing of anatomic models for surgical planning of heart transplantation in patients with univentricular heart. *The Journal of Thoracic and Cardiovascular Surgery*. 2008;136:1098-1099.
58. Riesenkampff E, Rietdorf U, Wolf I, Schnackenburg B, Ewert P, Huebler M, Alexi-Meskishvili V, Anderson RH, Engel N, Meinzer H-P, Hetzer R, Berger F and Kuehne T. The practical clinical value of three-dimensional models of complex congenitally malformed hearts. *The Journal of thoracic and cardiovascular surgery*. 2009;138:571-80.
59. Deal BJ and Jacobs ML. Management of the failing Fontan circulation. *Heart*. 2012;98:1098-104.
60. Haggerty CM, Fynn-Thompson F, McElhinney DB, Valente AM, Saikrishnan N, Del Nido PJ and Yoganathan AP. Experimental and numeric investigation of Impella pumps as cavopulmonary assistance for a failing Fontan. *J Thorac Cardiovasc Surg*. 2012;144:563-9.
61. Lacour-Gayet FG, Lanning CJ, Stoica S, Wang R, Rech BA, Goldberg S and Shandas R. An artificial right ventricle for failing fontan: in vitro and computational study. *Ann Thorac Surg*. 2009;88:170-6.
62. Almond CS, Mayer JE, Jr., Thiagarajan RR, Blume ED, del Nido PJ and McElhinney DB. Outcome after Fontan failure and takedown to an intermediate palliative circulation. *Ann Thorac Surg*. 2007;84:880-7.
63. Bernstein D, Naftel D, Chin C, Addonizio LJ, Gamberg P, Blume ED, Hsu D, Canter CE, Kirklin JK and Morrow WR. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. *Circulation*. 2006;114:273-80.
64. Rossano JW, Woods RK, Berger S, Gaynor JW, Ghanayem N, Morales DLS, Ravishankar C, Mitchell ME, Shah TK, Mahr C, Tweddell JS, Adachi I, Zangwill S, Wearden PD, Icenogle TB, Jaquiss RD and Rychik J. Mechanical support as failure intervention in patients with cavopulmonary shunts (MFICS): Rationale and aims of a new registry of mechanical circulatory support in single ventricle patients. *Congenital Heart Disease*. 2013;8:182-186.
65. Di Molfetta A, Amodeo A, Fresiello L, Trivella MG, Iacobelli R, Pilati M and Ferrari G. Simulation of Ventricular, Cavo-Pulmonary, and Biventricular Ventricular Assist Devices in Failing Fontan. *Artif Organs*. 2015;39:550-8.
66. Niebler RA, Shah TK, Mitchell ME, Woods RK, Zangwill SD, Tweddell JS, Berger S and Ghanayem NS. Ventricular Assist Device in Single-Ventricle Heart Disease and a Superior Cavopulmonary Anastomosis. *Artif Organs*. 2015.
67. Marelli AJ, Ionescu-Ittu R, Mackie AS, Guo L, Dendukuri N and Kaouache M. Lifetime prevalence of congenital heart disease in the general population from 2000 to 2010. *Circulation*. 2014;130:749-56.
68. Marelli AJ, Mackie AS, Ionescu-Ittu R, Rahme E and Pilote L. Congenital heart disease in the general population: Changing prevalence and age distribution. *Circulation*. 2007;115:163-172.
69. Khairy P, Van Hare GF, Balaji S, Berul CI, Cecchin F, Cohen MI, Daniels CJ, Deal BJ, Dearani JA, Groot N, Dubin AM, Harris L, Janousek J, Kanter RJ, Karpawich PP, Perry JC, Seslar SP, Shah MJ, Silka MJ, Triedman JK, Walsh EP and Warnes CA. PACES/HRS Expert Consensus Statement on the Recognition and Management of Arrhythmias in Adult Congenital Heart Disease: developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American

Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD). *Heart Rhythm*. 2014;11:e102-65.
70. Stefanescu A, Macklin EA, Lin E, Dudzinski DM, Johnson J, Kennedy KF, Jacoby D, DeFaria Yeh D, Lewis GD, Yeh RW, Liberthson R, Lui G and Bhatt AB. Usefulness of the Seattle Heart Failure Model to identify adults with congenital heart disease at high risk of poor outcome. *Am J Cardiol*. 2014;113:865-70.
71. Zomer AC, Vaartjes I, Uiterwaal CS, van der Velde ET, van den Merkhof LF, Baur LH, Ansink TJ, Cozijnsen L, Pieper PG, Meijboom FJ, Grobbee DE and Mulder BJ. Circumstances of death in adult congenital heart disease. *Int J Cardiol*. 2012;154:168-72.
72. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH, Shannon KM, Temple J, Rosenthal E, Zimmerman FJ, Davis A, Karpawich PP, Al Ahmad A, Vetter VL, Kertesz NJ, Shah M, Snyder C, Stephenson E, Emmel M, Sanatani S, Kanter R, Batra A and Collins KK. Resynchronization therapy in pediatric and congenital heart disease patients: an international multicenter study. *J Am Coll Cardiol*. 2005;46:2277-83.
73. Everitt MD, Donaldson AE, Stehlik J, Kaza AK, Budge D, Alharethi R, Bullock Ea, Kfoury AG and Yetman AT. Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). *Journal of Heart and Lung Transplantation*. 2011;30:395-401.
74. Rodriguez FH, 3rd, Moodie DS, Parekh DR, Franklin WJ, Morales DL, Zafar F, Adams GJ, Friedman RA and Rossano JW. Outcomes of heart failure-related hospitalization in adults with congenital heart disease in the United States. *Congenit Heart Dis*. 2013;8:513-9.
75. Nollert G, Fischlein T, Bouterwek S, Bohmer C, Klinner W and Reichart B. Long-term survival in patients with repair of tetralogy of Fallot: 36-year follow-up of 490 survivors of the first year after surgical repair. *J Am Coll Cardiol*. 1997;30:1374-83.
76. Gratz A, Hess J and Hager A. Self-estimated physical functioning poorly predicts actual exercise capacity in adolescents and adults with congenital heart disease. *Eur Heart J*. 2009;30:497-504.
77. Cuypers JA, Menting ME, Konings EE, Opic P, Utens EM, Helbing WA, Witsenburg M, van den Bosch AE, Ouhlous M, van Domburg RT, Rizopoulos D, Meijboom FJ, Boersma E, Bogers AJ and Roos-Hesselink JW. Unnatural history of tetralogy of Fallot: prospective follow-up of 40 years after surgical correction. *Circulation*. 2014;130:1944-53.
78. Maxwell BG, Wong JK, Sheikh AY, Lee PH and Lobato RL. Heart transplantation with or without prior mechanical circulatory support in adults with congenital heart disease. *Eur J Cardiothorac Surg*. 2014;45:842-6.
79. Selzman CH, Desjardins G, Patel AN, Davis E, Dick S and Stehlik J. Complications associated with the use of left ventricular assist device therapy in an adult patient with Ebstein's anomaly. *Ann Thorac Surg*. 2012;93:297-9.
80. Maly J, Netuka I, Besik J, Dorazilova Z, Pirk J and Szarszoi O. Bridge to transplantation with long-term mechanical assist device in adults after the Mustard procedure. *J Heart Lung Transplant*. 2015;34:1177-81.
81. Huang J and Slaughter MS. HeartWare ventricular assist device placement in a patient with congenitally corrected transposition of the great arteries. *The Journal of Thoracic and Cardiovascular Surgery*. 2013;145:e23-e25.
82. Joyce DL, Crow SS, John R, St Louis JD, Braunlin Ea, Pyles La, Kofflin P and Joyce LD. Mechanical circulatory support in patients with heart failure secondary to transposition of the great arteries. *The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation*. 2010;29:1302-1305.

83. Derk G, Laks H, Biniwale R, Patel S, De LaCruz K, Mazor E, Williams R, Valdovinos J, Levi DS, Reardon L and Aboulhosn J. Novel techniques of mechanical circulatory support for the right heart and Fontan circulation. *Int J Cardiol*. 2014;176:828-32.
84. Jabbar AA, Franklin WJ, Simpson L, Civitello AB, Delgado RM, 3rd and Frazier OH. Improved systemic saturation after ventricular assist device implantation in a patient with decompensated dextro-transposition of the great arteries after the fontan procedure. *Tex Heart Inst J*. 2015;42:40-3.
85. Valeske K, Yerebakan C, Mueller M and Akintuerk H. Urgent implantation of the Berlin Heart Excor biventricular assist device as a total artificial heart in a patient with single ventricle circulation. *J Thorac Cardiovasc Surg*. 2014;147:1712-4.
86. Newcomb AE, Negri JC, Brizard CP and d'Udekem Y. Successful left ventricular assist device bridge to transplantation after failure of a fontan revision. *J Heart Lung Transplant*. 2006;25:365-7.
87. Ryan TD, Jefferies JL, Zafar F, Lorts A and Morales DLS. The Evolving Role of the Total Artificial Heart in the Management of End-Stage Congenital Heart Disease and Adolescents. *ASAIO Journal*. 2015;61:8-14.
88. Rossano JW, Goldberg DJ, Fuller S, Ravishankar C, Montenegro LM and Gaynor JW. Successful use of the total artificial heart in the failing Fontan circulation. *The Annals of thoracic surgery*. 2014;97:1438-40.
89. Frazier OH, Gregoric ID and Messner GN. Total circulatory support with an LVAD in an adolescent with a previous Fontan procedure. *Tex Heart Inst J*. 2005;32:402-4.
90. Pretre R, Haussler A, Bettex D and Genoni M. Right-sided univentricular cardiac assistance in a failing Fontan circulation. *Ann Thorac Surg*. 2008;86:1018-20.
91. Massad MG, Cook DJ, Schmitt SK, Smedira NG, McCarthy JF, Vargo RL and McCarthy PM. Factors influencing HLA sensitization in implantable LVAD recipients. *Ann Thorac Surg*. 1997;64:1120-5.
92. Stringham JC, Bull DA, Fuller TC, Kfoury AG, Taylor DO, Renlund DG and Karwande SV. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. *J Heart Lung Transplant*. 1999;18:160-5.
93. Pagani FD, Dyke DB, Wright S, Cody R and Aaronson KD. Development of anti-major histocompatibility complex class I or II antibodies following left ventricular assist device implantation: effects on subsequent allograft rejection and survival. *J Heart Lung Transplant*. 2001;20:646-53.
94. Alba AC, Tinckam K, Foroutan F, Nelson LM, Gustafsson F, Sander K, Bruunsgaard H, Chih S, Hayes H, Rao V, Delgado D and Ross HJ. Factors associated with anti-human leukocyte antigen antibodies in patients supported with continuous-flow devices and effect on probability of transplant and post-transplant outcomes. *J Heart Lung Transplant*. 2015;34:685-92.
95. Arnaoutakis GJ, George TJ, Kilic A, Weiss ES, Russell SD, Conte JV and Shah AS. Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: Update in a modern cohort. *The Journal of Thoracic and Cardiovascular Surgery*. 2011;142:1236-1245.e1.
96. Joyce DL, Southard RE, Torre-Amione G, Noon GP, Land GA and Loebe M. Impact of left ventricular assist device (LVAD)-mediated humoral sensitization on post-transplant outcomes. *J Heart Lung Transplant*. 2005;24:2054-9.
97. O'Connor MJ, Lind C, Tang X, Gossett J, Weber J, Monos D and Shaddy RE. Persistence of anti-human leukocyte antibodies in congenital heart disease late after surgery using allografts and whole blood. *J Heart Lung Transplant*. 2013;32:390-7.

98. Shaddy RE, Hunter DD, Osborn KA, Lambert LM, Minich LL, Hawkins JA, McGough EC and Fuller TC. Prospective analysis of HLA immunogenicity of cryopreserved valved allografts used in pediatric heart surgery. *Circulation*. 1996;94:1063-7.
99. Meyer SR, Ross DB, Forbes K, Hawkins LE, Halpin AM, Nahirniak SN, Rutledge JM, Rebeyka IM and Campbell PM. Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery. *J Thorac Cardiovasc Surg*. 2007;133:1517-23.
100. Laing BJ, Ross DB, Meyer SR, Campbell P, Halpin AM, West LJ and Rebeyka IM. Glutaraldehyde treatment of allograft tissue decreases allosensitization after the Norwood procedure. *J Thorac Cardiovasc Surg*. 2010;139:1402-8.
101. Gonzalez-Stawinski GV, Cook DJ, Chang AS, Banbury MK, Navia JL, Hoercher K, Lober C, Atik FA, Taylor DO, Yamani MH, Young JB, Starling RC and Smedira NG. Ventricular assist devices and aggressive immunosuppression: looking beyond overall survival. *J Heart Lung Transplant*. 2006;25:613-8.
102. Higgins R, Kirklin JK, Brown RN, Rayburn BK, Wagoner L, Oren R, Miller L, Flattery M and Bourge RC. To induce or not to induce: do patients at greatest risk for fatal rejection benefit from cytolytic induction therapy? *J Heart Lung Transplant*. 2005;24:392-400.
103. Lampert BC and Teuteberg JJ. Right ventricular failure after left ventricular assist devices. *J Heart Lung Transplant*. 2015;34:1123-30.
104. Kang G, Ha R and Banerjee D. Pulmonary artery pulsatility index predicts right ventricular failure after left ventricular assist device implantation. *J Heart Lung Transplant*. 2015.
105. Miller JR, Epstein DJ, Henn MC, Guthrie T, Schuessler RB, Simpson KE, Canter CE, Eghtesady P and Boston US. Early Biventricular Assist Device Use In Children: A Single Center Review Of 31 Patients. *ASAIO J*. 2015.
106. Raina A, Seetha Rammohan HR, Gertz ZM, Rame JE, Woo YJ and Kirkpatrick JN. Postoperative right ventricular failure after left ventricular assist device placement is predicted by preoperative echocardiographic structural, hemodynamic, and functional parameters. *J Card Fail*. 2013;19:16-24.
107. Karimova A, Pockett CR, Lasuen N, Dedieu N, Rutledge J, Fenton M, Vanderpluym C, Rebeyka IM, Dominguez TE and Buchholz H. Right ventricular dysfunction in children supported with pulsatile ventricular assist devices. *The Journal of thoracic and cardiovascular surgery*. 2014;147:1691-1697.e1.
108. Kormos RL, Teuteberg JJ, Pagani FD, Russell SD, John R, Miller LW, Massey T, Milano CA, Moazami N and Sundareswaran KS. Right ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist device: incidence, risk factors, and effect on outcomes. *The Journal of thoracic and cardiovascular surgery*. 2010;139:1316-1324.
109. Slaughter MS, Pagani FD, McGee EC, Birks EJ, Cotts WG, Gregoric I, Howard Frazier O, Icenogle T, Najjar SS, Boyce SW, Acker Ma, John R, Hathaway DR, Najarian KB and Aaronson KD. HeartWare ventricular assist system for bridge to transplant: Combined results of the bridge to transplant and continued access protocol trial. *Journal of Heart and Lung Transplantation*. 2013;32:675-683.
110. Lalonde SD, Alba AC, Rigobon A, Ross HJ, Delgado DH, Billia F, McDonald M, Cusimano RJ, Yau TM and Rao V. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. *J Card Surg*. 2013;28:604-10.
111. Patel ND, Weiss ES, Schaffer J, Ullrich SL, Rivard DC, Shah AS, Russell SD and Conte JV. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile HeartMate I and axial-flow HeartMate II devices. *Ann Thorac Surg*. 2008;86:832-40; discussion 832-40.

112. Popov AF, Hosseini MT, Zych B, Mohite P, Hards R, Krueger H, Bahrami T, Amrani M and Simon AR. Clinical experience with HeartWare left ventricular assist device in patients with end-stage heart failure. *Ann Thorac Surg*. 2012;93:810-5.
113. Jordan LC, Ichord RN, Reinhartz O, Humpl T, Pruthi S, Tjossem C and Rosenthal DN. Neurological Complications and Outcomes in the Berlin Heart EXCOR® Pediatric Investigational Device Exemption Trial. *Journal of the American Heart Association*. 2015;4:e001429--e001429-.
114. Strueber M, O'Driscoll G, Jansz P, Khaghani A, Levy WC and Wieselthaler GM. Multicenter evaluation of an intrapericardial left ventricular assist system. *J Am Coll Cardiol*. 2011;57:1375-82.
115. Stein ML, Dao DT, Doan LN, Reinhartz O, Maeda K, Hollander SA, Yeh J, Kaufman BD, Almond CS and Rosenthal DN. Ventricular assist devices in a contemporary pediatric cohort: morbidity, functional recovery, and survival. *J Heart Lung Transplant*. 2015.
116. Byrnes JW, Prodhan P, Williams BA, Schmitz ML, Moss MM, Dyamenahalli U, McKamie W, Morrow WR, Imamura M and Bhutta AT. Incremental reduction in the incidence of stroke in children supported with the Berlin EXCOR ventricular assist device. *Ann Thorac Surg*. 2013;96:1727-33.
117. Starling RC, Moazami N, Silvestry SC, Ewald G, Rogers JG, Milano CA, Rame JE, Acker MA, Blackstone EH and Ehrlinger J. Unexpected abrupt increase in left ventricular assist device thrombosis. *New England Journal of Medicine*. 2014;370:33-40.
118. Katz JN, Adamson RM, John R, Tatooles A, Sundareswaran K, Kallel F, Farrar DJ and Jorde UP. Safety of reduced anti-thrombotic strategies in HeartMate II patients: A one-year analysis of the US-TRACE Study. *J Heart Lung Transplant*. 2015.
119. Conway J, Louis JS, Morales DL, Law S, Tjossem C and Humpl T. Delineating Survival Outcomes in Children< 10 Kg Bridged to Transplant or Recovery With the Berlin Heart EXCOR Ventricular Assist Device. *JACC: Heart Failure*. 2014.
120. Rhee E, Hurst R, Pukenas B, Ichord R, Cahill AM, Rossano J, Fuller S and Lin K. Mechanical embolectomy for ischemic stroke in a pediatric ventricular assist device patient. *Pediatr Transplant*. 2014;18:E88-92.
121. Nienaber JJ, Kusne S, Riaz T, Walker RC, Baddour LM, Wright AJ, Park SJ, Vikram HR, Keating MR, Arabia FA, Lahr BD and Sohail MR. Clinical manifestations and management of left ventricular assist device-associated infections. *Clin Infect Dis*. 2013;57:1438-48.
122. Levy DT, Guo Y, Simkins J, Puius YA, Muggia VA, Goldstein DJ, D'Alessandro DA and Minamoto GY. Left ventricular assist device exchange for persistent infection: a case series and review of the literature. *Transpl Infect Dis*. 2014;16:453-60.
123. Goldstein DJ, Naftel D, Holman W, Bellumkonda L, Pamboukian SV, Pagani FD and Kirklin J. Continuous-flow devices and percutaneous site infections: clinical outcomes. *J Heart Lung Transplant*. 2012;31:1151-7.
124. Koval CE, Thuita L, Moazami N and Blackstone E. Evolution and impact of drive-line infection in a large cohort of continuous-flow ventricular assist device recipients. *J Heart Lung Transplant*. 2014;33:1164-72.
125. Hannan MM, Husain S, Mattner F, Danziger-Isakov L, Drew RJ, Corey GR, Schueler S, Holman WL, Lawler LP, Gordon SM, Mahon NG, Herre JM, Gould K, Montoya JG, Padera RF, Kormos RL, Conte JV and Mooney ML. Working formulation for the standardization of definitions of infections in patients using ventricular assist devices. *J Heart Lung Transplant*. 2011;30:375-84.
126. Chamogeorgakis T, Koval CE, Smedira NG, Starling RC and Gonzalez-Stawinski GV. Outcomes associated with surgical management of infections related to the HeartMate II left ventricular assist device: Implications for destination therapy patients. *J Heart Lung Transplant*. 2012;31:904-6.

127. Dean D, Kallel F, Ewald GA, Tatooles A, Sheridan BC, Brewer RJ, Caldeira C, Farrar DJ and Akhter SA. Reduction in driveline infection rates: Results from the HeartMate II Multicenter Driveline Silicone Skin Interface (SSI) Registry. *J Heart Lung Transplant*. 2015;34:781-9.
128. Yee DL, O'Brien SH and Young G. Pharmacokinetics and pharmacodynamics of anticoagulants in paediatric patients. *Clin Pharmacokinet*. 2013;52:967-80.
129. Giglia TM, Massicotte MP, Tweddell JS, Barst RJ, Bauman M, Erickson CC, Feltes TF, Foster E, Hinoki K, Ichord RN, Kreutzer J, McCrindle BW, Newburger JW, Tabbutt S, Todd JL and Webb CL. Prevention and treatment of thrombosis in pediatric and congenital heart disease: a scientific statement from the American Heart Association. *Circulation*. 2013;128:2622-703.
130. Weintraub L, Driscoll C, Aydin S, Lamour JM, Weinstein S and Manwani D. Challenging diagnosis and treatment of HIT in child with ventricular assistance device. *Pediatr Transplant*. 2015;19:E152-6.
131. Badiye A, Hernandez GA and Chaparro S. Argatroban as novel therapy for suspected thrombosis in patients with continuous-flow left ventricle assist device and hemolysis. *ASAIO J*. 2014;60:361-5.
132. Ghanny S and Crowther M. Treatment with novel oral anticoagulants: indications, efficacy and risks. *Curr Opin Hematol*. 2013;20:430-6.
133. Rutledge JM, Chakravarti S, Massicotte MP, Buchholz H, Ross DB and Joashi U. Antithrombotic strategies in children receiving long-term Berlin Heart EXCOR ventricular assist device therapy. *J Heart Lung Transplant*. 2013;32:569-73.
134. Moffett BS, Cabrera AG, Teruya J and Bomgaars L. Anticoagulation therapy trends in children supported by ventricular assist devices: a multi-institutional study. *ASAIO J*. 2014;60:211-5.
135. Monagle P and Massicotte P. Developmental haemostasis: secondary haemostasis. *Semin Fetal Neonatal Med*. 2011;16:294-300.
136. Joyce D, Crow S, Li Z, Joyce L, Milano C, Rogers J, Villamizar-Ortiz N and Chen D. Pilot investigation of a novel testing strategy for bleeding in ventricular assist device recipients. *J Heart Lung Transplant*. 2012;31:750-6.
137. Dietrich K, Stang L, van Ryn J and Mitchell LG. Assessing the anticoagulant effect of dabigatran in children: an in vitro study. *Thromb Res*. 2015;135:630-5.
138. Ignjatovic V, Barnes C, Newall F, Hamilton S, Burgess J and Monagle P. Point of care monitoring of oral anticoagulant therapy in children: comparison of CoaguChek Plus and Thrombotest methods with venous international normalised ratio. *Thromb Haemost*. 2004;92:734-7.
139. Ryerson LM, Bruce AK, Lequier L, Kuhle S, Massicotte MP and Bauman ME. Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy. *ASAIO J*. 2014;60:559-63.
140. Byrnes JW, Bhutta AT, Rettiganti MR, Gomez A, Garcia X, Dyamenahalli U, Johnson C, Jaquiss RD, Imamura M and Prodhan P. Steroid therapy attenuates acute phase reactant response among children on ventricular assist device support. *Ann Thorac Surg*. 2015;99:1392-8.
141. Ahmad T, Wang T, O'Brien EC, Samsky MD, Pura JA, Lokhnygina Y, Rogers JG, Hernandez AF, Craig D, Bowles DE, Milano CA, Shah SH, Januzzi JL, Felker GM and Patel CB. Effects of left ventricular assist device support on biomarkers of cardiovascular stress, fibrosis, fluid homeostasis, inflammation, and renal injury. *JACC Heart Fail*. 2015;3:30-9.
142. Grosman-Rimon L, McDonald MA, Jacobs I, Tumiati LC, Pollock Bar-Ziv S, Shogilev DJ, Mociornita AG, Ghashghai A, Chruscinski A, Cherney DZ and Rao V. Markers of

inflammation in recipients of continuous-flow left ventricular assist devices. *ASAIO J*. 2014;60:657-63.
143. Hu J, Mondal NK, Sorensen EN, Cai L, Fang HB, Griffith BP and Wu ZJ. Platelet glycoprotein Ibalpha ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices. *J Heart Lung Transplant*. 2014;33:71-9.
144. Voeller RK, Melby SJ, Grizzell BE and Moazami N. Novel use of plasmapheresis in a patient with heparin-induced thrombocytopenia requiring urgent insertion of a left ventricular assist device under cardiopulmonary bypass. *J Thorac Cardiovasc Surg*. 2010;140:e56-8.
145. Esnault P, Gaillard PE, Cotte J, Cungi PJ, Beaume J and Prunet B. Haemodialysis before emergency surgery in a patient treated with dabigatran. *Br J Anaesth*. 2013;111:776-7.
146. Estep JD, Stainback RF, Little SH, Torre G and Zoghbi WA. The role of echocardiography and other imaging modalities in patients with left ventricular assist devices. *JACC Cardiovasc Imaging*. 2010;3:1049-64.
147. Stainback RF, Estep JD, Agler DA, Birks EJ, Bremer M, Hung J, Kirkpatrick JN, Rogers JG and Shah NR. Echocardiography in the Management of Patients with Left Ventricular Assist Devices: Recommendations from the American Society of Echocardiography. *J Am Soc Echocardiogr*. 2015;28:853-909.
148. Estep JD, Chang SM, Bhimaraj A, Torre-Amione G, Zoghbi WA and Nagueh SF. Imaging for ventricular function and myocardial recovery on nonpulsatile ventricular assist devices. *Circulation*. 2012;125:2265-77.
149. Ibrahim M and Yacoub MH. Bridge to recovery and weaning protocols. *Heart Fail Clin*. 2014;10:S47-55.
150. Irving CA, Crossland DS, Haynes S, Griselli M, Hasan A and Kirk R. Evolving experience with explantation from Berlin Heart EXCOR ventricular assist device support in children. *J Heart Lung Transplant*. 2014;33:211-3.
151. Dandel M, Knosalla C and Hetzer R. Contribution of ventricular assist devices to the recovery of failing hearts: a review and the Berlin Heart Center Experience. *Eur J Heart Fail*. 2014;16:248-63.
152. Dandel M, Weng Y, Siniawski H, Potapov E, Drews T, Lehmkuhl HB, Knosalla C and Hetzer R. Prediction of cardiac stability after weaning from left ventricular assist devices in patients with idiopathic dilated cardiomyopathy. *Circulation*. 2008;118:S94-105.
153. Forest SJ, Bello R, Friedmann P, Casazza D, Nucci C, Shin JJ, D'Alessandro D, Stevens G and Goldstein DJ. Readmissions after ventricular assist device: etiologies, patterns, and days out of hospital. *Ann Thorac Surg*. 2013;95:1276-81.
154. Hasin T, Marmor Y, Kremers W, Topilsky Y, Severson CJ, Schirger Ja, Boilson Ba, Clavell AL, Rodeheffer RJ, Frantz RP, Edwards BS, Pereira NL, Stulak JM, Joyce L, Daly R, Park SJ and Kushwaha SS. Readmissions after implantation of axial flow left ventricular assist device. *Journal of the American College of Cardiology*. 2013;61:153-163.
155. Smedira NG, Hoercher KJ, Lima B, Mountis MM, Starling RC, Thuita L, Schmuhl DM and Blackstone EH. Unplanned hospital readmissions after HeartMate II implantation: frequency, risk factors, and impact on resource use and survival. *JACC Heart Fail*. 2013;1:31-9.
156. Tsiouris A, Paone G, Nemeh HW, Brewer RJ and Morgan JA. Factors determining post-operative readmissions after left ventricular assist device implantation. *J Heart Lung Transplant*. 2014;33:1041-7.
157. O'Connor MJ, Menteer J, Chrisant MR, Monos D, Lind C, Levine S, Gaynor JW, Hanna BD, Paridon SM, Ravishankar C and Kaufman BD. Ventricular assist device-associated anti-

human leukocyte antigen antibody sensitization in pediatric patients bridged to heart transplantation. *J Heart Lung Transplant*. 2010;29:109-16.
158. Yang J, Schall C, Smith D, Kreuser L, Zamberlan M, King K and Gajarski R. HLA Sensitization in Pediatric Pre-transplant Cardiac Patients Supported by Mechanical Assist Devices: the Utility of Luminex. *The Journal of Heart and Lung Transplantation*. 2009;28:123-129.
159. Hong BJ, Delaney M, Guynes A, Warner P, McMullan DM, Kemna MS, Boucek RJ and Law YM. Human leukocyte antigen sensitization in pediatric patients exposed to mechanical circulatory support. *ASAIO J*. 2014;60:317-21.
160. Ben Gal T, Piepoli MF, Corra U, Conraads V, Adamopoulos S, Agostoni P, Piotrowicz E, Schmid JP, Seferovic PM, Ponikowski P, Filippatos G and Jaarsma T. Exercise programs for LVAD supported patients: A snapshot from the ESC affiliated countries. *Int J Cardiol*. 2015;201:215-219.
161. Kerrigan DJ, Williams CT, Ehrman JK, Saval MA, Bronsteen K, Schairer JR, Swaffer M, Brawner CA, Lanfear DE, Selektor Y, Velez M, Tita C and Keteyian SJ. Cardiac rehabilitation improves functional capacity and patient-reported health status in patients with continuous-flow left ventricular assist devices: the Rehab-VAD randomized controlled trial. *JACC Heart Fail*. 2014;2:653-9.
162. Hayes K, Leet AS, Bradley SJ and Holland AE. Effects of exercise training on exercise capacity and quality of life in patients with a left ventricular assist device: a preliminary randomized controlled trial. *J Heart Lung Transplant*. 2012;31:729-34.
163. Scheiderer R, Belden C, Schwab D, Haney C and Paz J. Exercise guidelines for inpatients following ventricular assist device placement: a systematic review of the literature. *Cardiopulm Phys Ther J*. 2013;24:35-42.
164. Furness S, Hyslop-St George C, Pound B, Earle M, Maurich A, Rice D and Humpl T. Development of an interprofessional pediatric ventricular assist device support team. *ASAIO J*. 2008;54:483-5.
165. Lateef F. Simulation-based learning: Just like the real thing. *J Emerg Trauma Shock*. 2010;3:348-52.
166. Stahl MA and Richards NM. Ventricular assist devices: developing and maintaining a training and competency program. *J Cardiovasc Nurs*. 2002;16:34-43.
167. Swayze SC and Rich SE. Promoting safe use of medical devices. *Online J Issues Nurs*. 2012;17:9.
168. Weaver SJ, Dy SM and Rosen MA. Team-training in healthcare: a narrative synthesis of the literature. *BMJ Qual Saf*. 2014;23:359-72.